Contact

CAR-T Therapies with NonaCAR and NonaCarFx

CAR-T Therapies with Nona Biosciences

NonaCAR
NonaCarFx
Reporter Cell-Based Lead VH Validation
Human Primary CAR-T In Vitro Characterization

Unlocking New Frontiers in CAR-T Therapies with NonaCAR and NonaCarFx

Single-domain antibodies have transformed CAR-T cell therapies by virtue of their compact size, exceptional stability, high affinity, and manufacturability. However, traditional camelid nanobodies require labor-intensive and costly humanization processes, carrying the risk of inducing anti-drug antibodies in patients.

At Nona Biosciences, we stand at the forefront of this transformative wave. We take pride in partnering with CAR-T companies, offering them NonaCAR—a cutting-edge solution powered by next-generation Fully Human Heavy Chain Only Antibodies (HCAb); and NonaCarFx—an Innovative direct CAR-function-based HCAb library screening platform.

What Sets Nona Apart


NonaCAR:

Nona’s Fully human HCAb derived CAR

Fully human HCAb generated from Nona’s HCAb Harbour Mice® represents the ideal modality for CAR-based cell therapies. Unlike traditional approaches, fully human HCAbs have the potential to significantly reduce immunogenicity. Moreover, their compact size, simplified structure, and precisely calibrated binding properties offer versatility in CAR design. In the dynamic field of cell therapies, fully human HCAbs hold the promise of unlocking even greater therapeutic potential.

  • It will shorten the workflow for positive plasma cell screening from months to a single day.

  • The high throughput screening with 14K or 20K chips dramatically decreases labor costs for screening more than 10,000 cells.

  • Direct screening with individual plasma cells prevents the diversity loss/bias during hybridoma screening.

Antibody Discovery in a “Single Day” by Beacon® Technology

Berkeley Lights Beacon® Optofluidic System

Beacon® can support the separation and screening of 10,000+ cells in a single run with one 14K or 20K OptoSelect chip. Enriched plasma cells are individually loaded into NanoPen chambers on the chip. Our proprietary medium preserves the viability and facilitates antibody secretion of these plasma cells. Multiple in-chip assays can be sequentially performed to screen those plasma cells, and the cells with desired signals wll beare selected and exported one by one through OEP technology. The entire workflow is completed in just one day.

High Throughput Chip

Each 20K OptoSelect chip has 20,000 individual NanoPen chambers and can separate and screen up to 20,000 cells within a single run.

Versatile In-Chip Assays

With real-time fluorescent microscopy technology, different assays could be performed in-chip for plasma cell screening, including:

  • Antigen beads binding assay
  • Cell binding assay
  • Competition assay
  • Reporter cell assay

All these advantages make SBC platform to become highly efficient and robust antibody discovery platform.

Precisely Single Cell Exporting

Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.

NonaCarFx:

Nona’s Innovative Direct CAR-Function-Based Express HCAb Library Screening Platform

With their elegantly simple single-chain structure, HCAbs enable the direct cloning of HCAb libraries into CAR-lentiviral vectors. This remarkable advancement, when combined with reporter cells and FACS sorting, has given rise to our groundbreaking Innovative Direct CAR-Function-Based Express HCAb Library Screening Platform-NonaCarFx.

  • It will shorten the workflow for positive plasma cell screening from months to a single day.

  • The high throughput screening with 14K or 20K chips dramatically decreases labor costs for screening more than 10,000 cells.

  • Direct screening with individual plasma cells prevents the diversity loss/bias during hybridoma screening.

Reporter Cell-Based Lead VH Validation

To streamline CAR-based screening, Nona Biosciences has pioneered a cutting-edge dual-readout reporter cell line. This innovation enables efficient and dependable assessments of lead VH candidates, expediting your research endeavors.

Human Primary CAR-T In Vitro Characterization

Our specialization lies in the meticulous in vitro characterization of CAR-T cells using human primary T cells. This comprehensive evaluation covers essential parameters, including cytotoxicity, cytokine production, proliferation, and phenotype analysis. Rest assured, it ensures the robust performance and functionality of your CAR-T cell products.

At Nona Biosciences, our mission is to drive the evolution of CAR-T therapies by harnessing the immense potential of Fully Human HCAb. We are unwavering in our commitment to provide exceptional services that contribute to the development of safe, effective, and innovative CAR-T treatments.

Reach out to us at bd@nonabio.com to explore our offerings and initiate a collaborative partnership for your next groundbreaking CAR-T project. Together, we can pioneer the future of CAR-T therapies.

Explore Our Other HCAb PLUS Projects

Explore our lorem ipsum
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound
Contact